Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach.
Harpreet K MandhairRamin RadpourMira WesterhuisYara BanzMagali HumbertMiroslav ArambasicJörn DengjelAndrew DaviesMario P TschanUrban NovakPublished in: Leukemia (2024)